BRIEF—BIOCAD and Shanghai Pharmaceuticals to build China-based plant

Russia’s BIOCAD and Shanghai Pharmaceuticals Holding (SPH) have agreed a deal to build a facility in China, to manufacture drug substances.

Two joint ventures will be established for the production, clinical development, registration, and marketing of several high-cost medicines based on monoclonal antibodies.

The signing ceremony took place on September 12 at the Eastern Economic Forum in Vladivostok, Russia.